Llwytho...
Pembrolizumab Improves Progression‐Free Survival in Relapsed/Refractory Hodgkin Lymphoma
In the phase III KEYNOTE‐204 trial, pembrolizumab significantly improved progression‐free survival compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin lymphoma (cHL), confirming pembrolizumab as the new standard of care in this setting.
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncologist |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley & Sons, Inc.
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330920/ https://ncbi.nlm.nih.gov/pubmed/32588926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0561 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|